Literature DB >> 28686818

Antipsychotic Medication Treatment Patterns in Adult Depression.

Tobias Gerhard1,2,3, T Scott Stroup4, Christoph U Correll5,6, Cecilia Huang3, Zhiqiang Tan7, Stephen Crystal3, Mark Olfson4.   

Abstract

OBJECTIVE: To characterize the role of antipsychotic medications in the community treatment of adult depression.
METHODS: We identified adults (aged 18-64 years) with new episodes of depression treatment (ICD-9-CM 296.2, 296.3, 300.4, or 311) in US national Medicaid data (2001-2010). Patients with alternative ICD-9-CM antipsychotic indications, such as schizophrenia or bipolar disorder, were excluded. Each patient was followed for at least 1 year to characterize antipsychotic and antidepressant treatment and emerging alternative antipsychotic indications. For patients without alternative indications through day 45 following start of antipsychotic treatment, antipsychotics were considered to be intended for treatment of depression. Among this group, we determined whether antipsychotic initiation was preceded by minimally adequate treatment with antidepressants, defined as active antidepressant treatment for ≥ 31 days prior to and including the day of antipsychotic initiation.
RESULTS: Within 1 year following onset, 14.0% of patients started an antipsychotic medication. A total of 41.3% of antipsychotic initiators developed an antipsychotic indication other than depression through day 45 following antipsychotic initiation, most often bipolar disorder or depression with psychotic features. The remaining 58.7% of antipsychotic initiators presumably started antipsychotics for nonpsychotic depression. Of these, 71.3% did not have minimally adequate antidepressant treatment prior to starting the antipsychotic medication.
CONCLUSION: Antipsychotic medications are used in approximately 1 in 7 patients with a new episode of depression. For 1 in 12 patients, the antipsychotic was considered to be intended for nonpsychotic depression. Almost three-quarters of these patients did not receive minimally adequate treatment with antidepressants prior to antipsychotic initiation. This pattern suggests potentially inappropriate and premature initiation of a drug class with substantial adverse effects and medical risks. © Copyright 2018 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28686818      PMCID: PMC8215589          DOI: 10.4088/JCP.16m10971

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

1.  The economic burden of depression in the United States: how did it change between 1990 and 2000?

Authors:  Paul E Greenberg; Ronald C Kessler; Howard G Birnbaum; Stephanie A Leong; Sarah W Lowe; Patricia A Berglund; Patricia K Corey-Lisle
Journal:  J Clin Psychiatry       Date:  2003-12       Impact factor: 4.384

Review 2.  Antipsychotic drugs and obesity.

Authors:  Christoph U Correll; Todd Lencz; Anil K Malhotra
Journal:  Trends Mol Med       Date:  2010-12-22       Impact factor: 11.951

3.  National trends in second-generation antipsychotic augmentation for nonpsychotic depression.

Authors:  Tobias Gerhard; Ayse Akincigil; Christoph U Correll; Neil J Foglio; Stephen Crystal; Mark Olfson
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

4.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

Review 5.  Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.

Authors:  Noah S Philip; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

6.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

7.  Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.

Authors:  Somaia Mohamed; Douglas L Leslie; Robert A Rosenheck
Journal:  J Clin Psychiatry       Date:  2009-05-05       Impact factor: 4.384

8.  Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

Authors:  Raymond W Lam; Sidney H Kennedy; Sophie Grigoriadis; Roger S McIntyre; Roumen Milev; Rajamannar Ramasubbu; Sagar V Parikh; Scott B Patten; Arun V Ravindran
Journal:  J Affect Disord       Date:  2009-08-11       Impact factor: 4.839

9.  Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes.

Authors:  Glen I Spielmans; Margit I Berman; Eftihia Linardatos; Nicholas Z Rosenlicht; Angela Perry; Alexander C Tsai
Journal:  PLoS Med       Date:  2013-03-12       Impact factor: 11.069

10.  Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.

Authors:  Narong Maneeton; Benchalak Maneeton; Manit Srisurapanont; Stephen D Martin
Journal:  BMC Psychiatry       Date:  2012-09-27       Impact factor: 3.630

View more
  6 in total

1.  Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015.

Authors:  Taeho Greg Rhee; Somaia Mohamed; Robert A Rosenheck
Journal:  J Clin Psychiatry       Date:  2018 Mar/Apr       Impact factor: 4.384

2.  Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.

Authors:  M Dold; L Bartova; J Mendlewicz; D Souery; A Serretti; S Porcelli; J Zohar; S Montgomery; S Kasper
Journal:  Acta Psychiatr Scand       Date:  2018-02-28       Impact factor: 6.392

3.  The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.

Authors:  Lucie Bartova; Gernot Fugger; Markus Dold; Alexander Kautzky; Marleen Margret Mignon Swoboda; Dan Rujescu; Joseph Zohar; Daniel Souery; Julien Mendlewicz; Stuart Montgomery; Chiara Fabbri; Alessandro Serretti; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2022-02-11       Impact factor: 5.176

4.  Association of Treatment With Antipsychotics, Antidepressants, or Both With Movement Disorders and Seizures Among Children and Adolescents With Depression in Korea.

Authors:  Soo Min Jeon; Hae-Young Park; Susan Park; Un Sun Chung; Jin-Won Kwon
Journal:  JAMA Netw Open       Date:  2022-04-01

5.  Factors Associated With Off-Label Utilization of Second-Generation Antipsychotics Among Publicly Insured Adults.

Authors:  Marcela Horvitz-Lennon; Rita Volya; Simon Hollands; Katya Zelevinsky; Andrew Mulcahy; Julie M Donohue; Sharon-Lise T Normand
Journal:  Psychiatr Serv       Date:  2021-06-02       Impact factor: 4.157

6.  Off-label use of antipsychotic medications in psychiatric inpatients in China: a national real-world survey.

Authors:  Juan Wang; Feng Jiang; Yating Yang; Yulong Zhang; Zhiwei Liu; Xiaorong Qin; Xueqin Tao; Tingfang Liu; Yuanli Liu; Yi-Lang Tang; Huanzhong Liu; Robert O Cotes
Journal:  BMC Psychiatry       Date:  2021-07-27       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.